Opus Genetics, Inc. (IRD)Healthcare | Biotechnology | Durham, United States | NasdaqCM
4.10 USD
-0.14
(-3.302%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 4.10 |
Hot Take ↕ | Oct. 10, 2026, 4:09 a.m. EDT
The investment case for Opus Genetics is currently broken by a catastrophic multi-year decline in share price. Over the last nine years, the stock has lost approximately 98% of its value, a trajectory that reflects a market verdict on the company's deteriorating fundamentals rather than a temporary dislocation. The business is hemorrhaging cash, with negative free cash flow and operating margins, and revenue has contracted sharply by nearly 74%. While the analyst consensus is aggressively bullish with a mean target implying massive upside, this ignores the reality that the company is burning through its limited cash reserves without a proven path to profitability. The recent FDA clearance for a Phase 3 trial offers a potential catalyst, but the balance sheet is fragile, and the historical data shows a pattern of repeated failures to sustain growth. The options market confirms this skepticism, with traders buying protection at lower strikes rather than betting on a near-term rally. Until the company demonstrates sustained revenue growth and a path to positive cash flow, the risk of permanent capital loss outweighs the speculative upside. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.325086 |
| AutoETS | 0.325092 |
| MSTL | 0.331070 |
| AutoTheta | 0.407041 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 9.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.094 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.118 |
| Market Cap | 341,102,880 |
| Forward P/E | -5.73 |
| Beta | 0.62 |
| Previous Name | Ocuphire Pharma, Inc. |
| Website | https://opusgtx.com |
As of Oct. 10, 2026, 4:09 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price (e.g., $2.50), while call interest remains concentrated near the money or slightly out-of-the-money. This asymmetry suggests a fear of further downside rather than a strong bullish conviction, despite the presence of some long-dated call open interest.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1199999 |
| Address1 | 8 Davis Drive |
| Address2 | Suite 220 |
| All Time High | 4,795.2 |
| All Time Low | 0.65 |
| Ask | 5.24 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,854,580 |
| Average Daily Volume3 Month | 2,401,373 |
| Average Volume | 2,401,373 |
| Average Volume10Days | 1,854,580 |
| Beta | 0.62 |
| Bid | 3.11 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | -0.157 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.1 |
| Current Ratio | 12.189 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.37 |
| Day Low | 4.08 |
| Display Name | Opus Genetics |
| Dividend Date | 1,604,620,800 |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -50,555,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.707 |
| Enterprise To Revenue | 29.271 |
| Enterprise Value | 288,494,880 |
| Eps Current Year | -0.93917 |
| Eps Forward | -0.715 |
| Eps Trailing Twelve Months | -1.27 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.4702 |
| Fifty Day Average Change | -0.37020016 |
| Fifty Day Average Change Percent | -0.08281512 |
| Fifty Two Week Change Percent | 111.999985 |
| Fifty Two Week High | 7.07 |
| Fifty Two Week High Change | -2.9700003 |
| Fifty Two Week High Change Percent | -0.4200849 |
| Fifty Two Week Low | 1.7 |
| Fifty Two Week Low Change | 2.3999999 |
| Fifty Two Week Low Change Percent | 1.4117646 |
| Fifty Two Week Range | 1.7 - 7.07 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,131,633,000,000 |
| Float Shares | 64,684,752 |
| Forward Eps | -0.715 |
| Forward P E | -5.734266 |
| Free Cashflow | -38,555,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 27 |
| Fullday Change | -0.12999964 |
| Fullday Change Percent | -3.0660293 |
| Fullday Price | 4.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -2.91853 |
| Gross Profits | -28,765,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.122320004 |
| Held Percent Institutions | 0.69268996 |
| Implied Shares Outstanding | 83,195,823 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.rexahn.com/cms/index.php/investor-relations/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,604,620,800 |
| Last Split Factor | 1:4 |
| Long Business Summary | Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina. |
| Long Name | Opus Genetics, Inc. |
| Market | us_market |
| Market Cap | 341,102,880 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_560534013 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -107,610,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 400,171,908 |
| Number Of Analyst Opinions | 17 |
| Open | 4.24 |
| Operating Cashflow | -40,667,000 |
| Operating Margins | -21.82781 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 984 884 6030 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.1 |
| Post Market Time | 1,792,021,564 |
| Prev Name | Ocuphire Pharma, Inc. |
| Previous Close | 4.24 |
| Price Eps Current Year | -4.3655567 |
| Price Hint | 4 |
| Price To Book | -26.114649 |
| Price To Sales Trailing12 Months | 34.608654 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.87 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.14 |
| Regular Market Change Percent | -3.30188 |
| Regular Market Day High | 4.37 |
| Regular Market Day Low | 4.08 |
| Regular Market Day Range | 4.08 - 4.37 |
| Regular Market Open | 4.24 |
| Regular Market Previous Close | 4.24 |
| Regular Market Price | 4.1 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 1,198,845 |
| Return On Assets | -0.48057997 |
| Return On Equity | -47.96523 |
| Revenue Growth | -0.738 |
| Revenue Per Share | 0.118 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 83,195,823 |
| Shares Percent Shares Out | 0.15640001 |
| Shares Short | 13,013,222 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,912,085 |
| Short Name | Opus Genetics, Inc. |
| Short Percent Of Float | 0.16450001 |
| Short Ratio | 2.62 |
| Source Interval | 15 |
| State | NC |
| Symbol | IRD |
| Target High Price | 20.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 13.41176 |
| Target Median Price | 13.0 |
| Total Cash | 88,812,000 |
| Total Cash Per Share | 1.068 |
| Total Debt | 36,204,000 |
| Total Revenue | 9,856,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.27 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.0712 |
| Two Hundred Day Average Change | 0.02880001 |
| Two Hundred Day Average Change Percent | 0.007074084 |
| Type Disp | Equity |
| Volume | 1,198,845 |
| Website | https://opusgtx.com |
| Zip | 27,713 |